Risks are growing in the sector
The explosion of demand for GLP-1 medications such as semaglutide and tirzepatide has propelled US medical spas into the center of a fast-changing and increasingly risky market.
Once marketed primarily as cosmetic or wellness destinations, medispas are now navigating heightened regulatory oversight, growing liability exposures, and a hardening insurance market.
According to Bobbie Williams (pictured), vice president and healthcare practice leader at Novatae Risk Group, the sector’s complexity lies in its hybrid identity. Medispas typically offer …